Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The Patient - Patient-Centered Outcomes Research
Published in: The Patient - Patient-Centered Outcomes Research 5/2015

01-10-2015 | Original Research Article

Using Best–Worst Scaling to Measure Caregiver Preferences for Managing their Child’s ADHD: A Pilot Study

Authors: Susan dosReis, Xinyi Ng, Emily Frosch, Gloria Reeves, Charles Cunningham, John F. P. Bridges

Published in: The Patient - Patient-Centered Outcomes Research | Issue 5/2015

Login to get access

Abstract

Background

Management of attention-deficit/hyperactivity disorder (ADHD) is a trade-off between caregivers’ concerns about the benefits versus the risks of evidence-based treatment. Few studies have used choice-based methods to assess what treatment attributes matter most to caregivers.

Objective

The aim was to develop and to pilot an instrument to elicit caregivers’ preferences for evidence-based management of their child’s ADHD.

Methods

Mixed methods were used to develop a Best–Worst Scaling (BWS) instrument, and quantitative methods were used to pilot the instrument. Primary caregivers of children with ADHD from two community organizations were recruited for the development (n = 21) and pilot (n = 37) phase. The instrument was a BWS case 2, where 18 management profiles are presented one at a time, with respondents indicating the one best and one worst feature of each profile. Profiles were developed using a main effects orthogonal array. The mean of best-minus-worse scores was estimated, and attribute importance was based on the sum of maximum minus minimum scores for each attribute. Feasibility of eliciting stated preferences was evaluated with t tests and 95 % confidence intervals.

Results

Seven attributes (medication, therapy, school, caregiver training, provider specialty, provider communication, and out-of-pocket costs) with three levels each were identified. All mean scores were significant except for pediatrician management of the child’s ADHD (p = 0.089). Caregiver training had the highest relative importance, followed by medication and provider communication.

Conclusions

The BWS instrument was a relatively simple measure, caregivers completed it independently, and it distinguished the relative importance of different attributes in managing a child’s ADHD.
Appendix
Available only for authorised users
Literature
1.
Perou R, Bitsko RH, Blumberg SJ, Pastor P, Ghandour RM, Gfroerer JC, et al. Mental health surveillance among children—United States, 2005–2011. MMWR Surv Summ. 2013;62(Suppl 2):1–35.
2.
Donfrancesco R, Marano A, Calderoni D, Mugnaini D, Thomas F, Di Trani M, et al. Prevalence of severe ADHD: an epidemiological study in the Italian regions of Tuscany and Latium. Epidemiol Psychiatr Sci. 2014;15:1–9.CrossRef
3.
Parr JR, Ward A, Inman S. Current practice in the management of attention deficit disorder with hyperactivity (ADHD). Child Care Health Dev. 2003;29(3):215–8.CrossRefPubMed
4.
Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry. 2003;160(6):1071–7.CrossRefPubMed
5.
Olfson M, Marcus S, Weissman MM, Jensen PS. National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry. 2002;41(5):514–21.CrossRefPubMed
6.
Zito JM, Safer DJ, dosReis S, Gardner JF, Magder L, Soeken K, et al. Psychotropic practice patterns for youth. A 10-year perspective. Arch Pediatr Adolesc Med. 2003;157:17–25.CrossRefPubMed
7.
Zito JM, Safer DJ, Riddle MA, Johnson RE, Speedie SM, Fox M. Prevalence variations in psychotropic treatment of children. J Child Adolesc Psychopharmacol. 1998;8(2):99–105.CrossRefPubMed
8.
Visser SN, Bitsko RH, Danielson ML, Perou R. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. MMWR Morb Mortal Wkly Rep. 2010;59(44):1439–43.
9.
American Academy of Child and Adolescent Psychiatry. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(10 Suppl):85S–121S.
10.
American Academy of Child and Adolescent Psychiatry. Practice parameters for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(2 Suppl):26S–49S.
11.
American Academy of Pediatrics. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108(4):1033–44.CrossRef
12.
The MTA Cooperative Group. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1088–96.CrossRef
13.
The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 1999;56:1073–86.CrossRef
14.
Ruel J, Hickey CP. Are too many children being treated with methylphenidate? Can J Psychiatry. 1992;37(8):570–2.PubMed
15.
Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, Hoven C, et al. Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry. 1999;38(7):797–804.CrossRefPubMed
16.
Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127(6):1102–10.PubMedCentralCrossRefPubMed
17.
Winterstein AG. Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies. Curr Psychiatry Rep. 2013;15(8):379.CrossRefPubMed
18.
Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304–13.CrossRefPubMed
19.
Hansen DL, Hansen EH. Caught in a balancing act: parents’ dilemmas regarding their ADHD child’s treatment with stimulant medication. Qual Health Res. 2006;16(9):1267–85.CrossRefPubMed
20.
McLeod JD, Fettes DL, Jensen PS, Pescosolido BA, Martin JK. Public knowledge, beliefs, and treatment preferences concerning attention-deficit hyperactivity disorder. Psychiatr Serv. 2007;58(5):626–31.PubMedCentralCrossRefPubMed
21.
dosReis S, Barksdale CL, Sherman A, Maloney K, Charach A. Stigmatizing experiences of parents of children newly diagnosed with ADHD. Psychiatr Serv. 2010;61(8):811–6.CrossRefPubMed
22.
dosReis S, Mychailyszyn MP, Evans-Lacko SE, Beltran A, Riley AW, Myers MA. The meaning of ADHD medication and parents’ initiation and continuity of treatment for their child. J Child Adolesc Psychopharmacol. 2009;19(4):377–83.PubMedCentralCrossRefPubMed
23.
dosReis S, Mychailyszyn MP, Myers MA, Riley AW. Coming to terms with ADHD: how urban African–American families come to seek care for their children. Psychiatr Serv. 2007;58(5):636–41.CrossRefPubMed
24.
Leslie LK, Plemmons D, Monn AR, Palinkas LA. Investigating ADHD treatment trajectories: listening to families’ stories about medication use. J Dev Behav Pediatr. 2007;28(3):179–88.CrossRefPubMed
25.
Bussing R, Zima BT, Gary FA, Garvan CW. Barriers to detection, help-seeking, and service use for children with ADHD symptoms. J Behav Health Serv Res. 2003;30(2):176–89.CrossRefPubMed
26.
dosReis S, Butz A, Lipkin P, Anixt J, Weiner CL, Chernoff R. Attitudes about stimulant medication for attention-deficit/hyperactivity disorder among African–American families in an inner city community. J Behav Health Serv Res. 2006;33(4):423–30.CrossRefPubMed
27.
Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects. J Am Acad Child Adolesc Psychiatry. 2004;43(5):559–67.CrossRefPubMed
28.
Swift JK, Callahan JL. The impact of client treatment preferences on outcome: a meta-analysis. J Clin Psychol. 2009;65(4):368–81.CrossRefPubMed
29.
Bussing R, Koro-Ljungberg ME, Gary F, Mason DM, Garvan CW. Exploring help-seeking for ADHD symptoms: a mixed-methods approach. Harv Rev Psychiatry. 2005;13(2):85–101.CrossRefPubMed
30.
dosReis S, Myers MA. Parental attitudes and involvement in psychopharmacological treatment for ADHD: a conceptual model. Int Rev Psychiatry. 2008;20(2):135–41.CrossRefPubMed
31.
32.
Muhlbacher A, Rudolph I, Lincke H-J, Nubling M. Preferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experiment. BMC Health Serv Res. 2009;9(1):149.PubMedCentralCrossRefPubMed
33.
Muhlbacher AC, Nubling M. Analysis of patients’ preferences: direct assessment and discrete-choice experiment in therapy of adults with attention-deficit hyperactivity disorder. Patient. 2010;3(4):285–94.CrossRefPubMed
34.
Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Making. 2005;25(1):56–70.CrossRefPubMed
35.
Waschbusch DA, Cunningham CE, Pelham WE, Rimas HL, Greiner AR, Gnagy EM, et al. A discrete choice conjoint experiment to evaluate parent preferences for treatment of young, medication naive children with ADHD. J Clin Child Adolesc Psychol. 2011;40(4):546–61.PubMedCentralCrossRefPubMed
36.
Mullins CD, Abdulhalim AM, Lavallee DC. Continuous patient engagement in comparative effectiveness research. J Am Med Assoc. 2012;307(15):1587–8.CrossRef
37.
Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health—a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–13.CrossRefPubMed
38.
Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, et al. Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ. 2012;21(6):730–41.CrossRefPubMed
39.
Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best–worst scaling. Expert Rev Pharmacoecon Outcomes Res. 2010;10(3):259–67.CrossRefPubMed
40.
41.
Louviere JJ, Flynn TN. Using best–worst scaling choice experiments to measure public perceptions and preferences for healthcare reform in Australia. Patient. 2010;3(4):275–83.CrossRefPubMed
42.
Tsai P-W, Gilmour SG, Mead R. Some new three-leel orthogonal main effects plans robust to model uncertainty. Stat Sin. 2004;14:1075–84.
43.
Gallego G, Bridges JF, Flynn T, Blauvelt BM, Niessen LW. Using best–worst scaling in horizon scanning for hepatocellular carcinoma technologies. Int J Technol Assess Health Care. 2012;28(3):339–46.CrossRefPubMed
44.
Finn A, Louviere JJ. Determining the appropriate response to evidence of public concern: the case of food safety. J Public Pol Health. 1992;11(1):12–25.
45.
Bussing R, Schoenberg NE, Perwien AR. Knowledge and information about ADHD: evidence of cultural differences among African–American and white parents. Soc Sci Med. 1998;46(7):919–28.CrossRefPubMed
46.
dosReis S, Zito JM, Safer DJ, Soeken KL, Mitchell JW, Ellwood LC. Parental perceptions and satisfaction with stimulant medication for attention-deficit/hyperactivity disorder. J Dev Behav Pediatr. 2003;24(3):155–62.CrossRefPubMed
47.
Chronis AM, Chacko A, Fabiano GA, Wymbs BT, Pelham WE Jr. Enhancements to the behavioral parent training paradigm for families of children with ADHD: review and future directions. Clin Child Fam Psychol Rev. 2004;7(1):1–27.CrossRefPubMed
Metadata
Title
Using Best–Worst Scaling to Measure Caregiver Preferences for Managing their Child’s ADHD: A Pilot Study
Authors
Susan dosReis
Xinyi Ng
Emily Frosch
Gloria Reeves
Charles Cunningham
John F. P. Bridges
Publication date
01-10-2015
Publisher
Springer International Publishing
Published in
The Patient - Patient-Centered Outcomes Research / Issue 5/2015
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI
https://doi.org/10.1007/s40271-014-0098-4

Other articles of this Issue 5/2015

The Patient - Patient-Centered Outcomes Research 5/2015 Go to the issue

Original Research Article

Qualitative Research on Fatigue Associated with Depression: Content Validity of the Fatigue Associated with Depression Questionnaire (FAsD-V2)

Review Article

Understanding Patient Preferences in Medication Nonadherence: A Review of Stated Preference Data

Original Research Article

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF

Practical Application

Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide

Original Research Article

Measuring the Preferences of Homeless Women for Cervical Cancer Screening Interventions: Development of a Best–Worst Scaling Survey

Systematic Review

Computer-Based Clinical Decision Support Systems and Patient-Reported Outcomes: A Systematic Review
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits